LYEL
NASDAQ
US
Lyell Immunopharma, Inc. - Common Stock
$21.21
▲ +$0.40
(+1.92%)
Vol 89K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$653.9M
ROE
-96.7%
Margin
-795122.0%
D/E
0.00
Beta
-0.08
52W
$8–$45
Wall Street Consensus
10 analysts · Apr 20262
Strong Buy
6
Buy
1
Hold
1
Sell
0
Strong Sell
80.0%
Buy Rating
Price Chart
Similar Stocks
RIGL
Rigel Pharmaceuticals Inc
P/E 6.9
$777.4M
LRMR
Larimar Therapeutics Inc
$326.1M
TRDA
Entrada Therapeutics Inc
$392.9M
VSTM
Verastem Inc
$581.5M
FDMT
4D Molecular Therapeutics Inc
$428.5M
IMMX
Immix Biopharma Inc
$275.6M
ABSI
Absci Corp
$524.8M
ASMB
Assembly Biosciences Inc
$537.9M
STTK
Shattuck Labs Inc
$231.0M
Earnings
Beat rate: 75.0%
Next Report
May 11, 2026
EPS Estimate: $-2.36
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-2.36 | — | — |
| Dec 2025 | $-2.28 | $-7.50 | $-5.22 |
| Sep 2025 | $-2.70 | $-2.13 | +$0.57 |
| Jun 2025 | $-3.66 | $-2.89 | +$0.77 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -85.7% | -85.6% | -85.6% | -85.6% | -96.7% | -96.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -537500.0% | -552328.3% | -552328.3% | -552328.3% | -794292.7% | -795121.9% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 7.62 | 7.65 | 7.65 | 7.65 | 10.30 | 10.25 |
Key Ratios
ROA (TTM)
-76.1%
P/S (TTM)
15948.51
P/B
0.5
EPS (TTM)
$-22.21
CF/Share
$-0.67
Rev Growth 3Y
-82.1%
52W High
$45.00
52W Low
$7.65
$7.65
52-Week Range
$45.00
How does LYEL compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
LYEL valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
15948.5
▲
124013%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
0.5
▼
80%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
LYEL profitability vs Biotechnology peers
ROE
-96.7%
▼
44%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-795122.0%
▼
277188%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-76.1%
▼
63%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
LYEL financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
10.3
▲
131%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
-0.1
▼
109%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
LYEL fundamentals radar
LYEL
Peer median
Industry
LYEL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
LYEL vs peers: key metrics
Latest News
No related news yet